Search of: "Addisons disease" - List Results

Modify Search Start Over

Condition or disease

Other terms

Country

State

City

Distance

Advanced Search

23 Studies found for: "Addisons disease"

Also searched for Primary adrenal insufficiency. See Search Details

List
By Topic
On Map
Search Details

Filters

Status

Recruitment :

Not yet recruiting
Recruiting
Enrolling by invitation
Active, not recruiting
Suspended
Terminated
Completed
Withdrawn
Unknown status^†

Expanded Access :

Available
No longer available
Temporarily not available
Approved for marketing

Eligibility Criteria

Age :
years OR Age Group :

Child (birth–17)
Adult (18–64)
Older Adult (65+)

Sex :

All
Female
Male

Accepts Healthy Volunteers

Study Type

All
Interventional (Clinical Trial)
Observational
-- Patient Registries
Expanded Access

Individual Patients

Intermediate-size Population

Treatment IND/Protocol

Study Results

All
With Results
Without Results

Study Phase

Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Not Applicable

Funder Type

NIH
Other U.S. Federal agency
Industry
All others (individuals, universities, organizations)

Study Documents

Study Protocols
Statistical Analysis Plans (SAPs)
Informed Consent Forms (ICFs)

Subscribe to RSS

Create an RSS feed from your search for:

"Addisons disease"

Need help? See RSS Feeds

Choose a feed type:

Show studies that were first added (first posted) in the last 14 days
Show studies added or modified (last update posted) in the last 14 days

Cancel

Download

Download the search results for:

"Addisons disease" (23 records)

Need help? See Downloading Content for Analysis

Number of Studies:

(PDF limited to 100 studies)

Download Table Contents (1 row per study)

Select table columns:

Select file format:

Cancel

For Advanced Users: Full Study Record XML Download

a zip file of the full study records in XML for all studies in the search results table (max 10000)
To download the XML for all public study records in our database; See Downloading All Study Content for Analysis

Warning

You have reached the maximum number of saved studies (100).

Please remove one or more studies before adding more.

NCT01657123

Unknown ^†

Exercise Capacity and Recovery in Addison's Disease

Addison's Disease

Other: ergometry

Interventional

Not Applicable

UMC Utrecht

Other

Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment

exercise capacity

All

18 Years to 50 Years (Adult)

NCT01657123

33088

January 2013

January 2014

August 3, 2012

University Medical Center Utrecht
Utrecht, Netherlands

NCT01063569

Completed

Glucocorticoid Treatment in Addison's Disease

Addison's Disease

Drug: Solu-Cortef (hydrocortisone)
Drug: Cortef (hydrocortisone)

Interventional

Phase 2
Phase 3

Haukeland University Hospital

Other

Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment

Morning (08-09) plasma ACTH
Health-Related Quality of Life; evaluated by SF-36 vitality scores and AddiQoL scores
Sleep; evaluated by Pittsburgh Sleep Quality Index (PSQI), and 7-days' Actigraph registration combined with self-reported sleep diary
(and 3 more...)

All

18 Years to 70 Years (Adult, Older Adult)

NCT01063569

3.2007.2343
2009-010917-61

February 2010

December 2012

February 5, 2010

March 20, 2013

Haukeland University Hospital
Bergen, Norway
Karolinska Institutet
Stockholm, Sweden
Uppsala University
Uppsala, Sweden

NCT01271296

Completed

Effects and Interactions of Liquorice and Grapefruit on Glucocorticoid Replacement Therapy in Addison's Disease

Addison Disease

Dietary Supplement: Liquorice
Dietary Supplement: Grapefruit Juice

Interventional

Not Applicable

Haukeland University Hospital

Other

Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Supportive Care

AUC Serum Cortisol - Levels of cortisol in serum during the first 2.6 hours after oral administration of cortisone acetate.
Serum Cortisol levels at the end of time-series sampling (t=160min)
Serum Cortisone levels at the end of time-series sampling (t=160min)
(and 15 more...)

All

18 Years to 80 Years (Adult, Older Adult)

NCT01271296

3.2007.2620 (REK)
17775 (NSD)
07/5829 (SHdir)
3.2007.2620

April 2008

January 2009

January 6, 2011

January 17, 2011

Haukeland University Hospital, Helse-Bergen HF
Bergen, Norway

NCT03210545

Not yet recruiting

A Study of Markers of Glucocorticoid Effects in Patients With Addisons Disease (DOSCORT)

Addison Disease

Drug: Dexamethasone

Interventional

Phase 4

Göteborg University

Other

Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single (Participant)
Primary Purpose: Treatment

Protein profile changes between physiological and supra physiological doses of dexamethasone.
Metabolite profile changes between physiological and supra physiological doses of dexamethasone.
Messenger RNA (mRNA)/miRNA profile changes between physiological and supra physiological doses of dexamethasone.
(and 9 more...)

All

20 Years to 60 Years (Adult)

NCT03210545

DOSCORT
2016-004078-16

March 1, 2018

May 31, 2018

July 7, 2017

November 27, 2017

Centrum for Endocrinology and Metabolism, Sahlgenska University Hospital
Gothenburg, Sweden

NCT01840189

Completed

Continuous Subcutaneous Hydrocortisone Infusion In Addison`s Disease and Type 1 Diabetes

Addison Disease
Type 1 Diabetes

Other: Cortef
Other: Solu-cortef

Interventional

Phase 2

Haukeland University Hospital

Other

Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment

nocturnal hypoglycemic events
o Nocturnal glycemic variability
hormone and metabolic profile
o Subjective health status

All

18 Years to 70 Years (Adult, Older Adult)

NCT01840189

2012/2218
2012/005516-26

May 2013

December 2016

April 25, 2013

February 1, 2017

Haukeland University Hospiatl
Bergen, Norway

NCT02096510

Recruiting

Ultradian Subcutaneous Hydrocortisone Infusion in Addison Disease and Congenital Adrenal Hyperplasia

Addison Disease
Adrenal Hyperplasia Congenital

Drug: Solu-Cortef
Drug: Cortef

Interventional

Phase 1
Phase 2

Haukeland University Hospital

Other

Allocation: Non-Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment

Serum cortisol -24 hours curve
Salivary cortisol - 24 hours curve
24 h urine cortisol and metabolites
(and 3 more...)

All

18 Years to 65 Years (Adult, Older Adult)

NCT02096510

2013/1738

August 2014

December 2017

March 26, 2014

December 21, 2016

University Hospital Helse Bergen
Bergen, Norway

NCT01847690

Unknown ^†

Effect of Cortisol on Physical Exertion in Patients With Primary Adrenal Failure

Addison Disease

Drug: Hydrocortisone

Interventional

Phase 2

Haukeland University Hospital

Other

Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment

O2 uptake
post- exercise hypoglycemic events
glycemic variability
(and 3 more...)

Female

18 Years to 70 Years (Adult, Older Adult)

NCT01847690

2012/2216
2012-005117-40

June 2013

January 2014

March 2014

May 7, 2013

December 2, 2013

Haukeland Universitetessykehus, Department of Medicine
Bergen, Norway

NCT00004313

Completed

Phase III Randomized, Double-Blind, Placebo-Controlled Study of Dehydroepiandrosterone Replacement for Primary Adrenal Insufficiency

Addison's Disease

Drug: dehydroepiandrosterone

Interventional

Phase 3

National Center for Research Resources (NCRR)
University of California, Los Angeles
Office of Rare Diseases (ORD)

NIH / Other

Allocation: Randomized
Masking: Double
Primary Purpose: Treatment

All

18 Years and older (Adult, Older Adult)

NCT00004313

199/11822
UCSD-1062

August 1995

October 19, 1999

June 24, 2005

NCT02152553

Completed

Biomarker(s) for Glucocorticoids

Addison Disease

Drug: Hydrocortisone
Drug: Placebo

Interventional

Not Applicable

Vastra Gotaland Region

Other

Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single (Participant)
Primary Purpose: Treatment

Protein profile changes between a state of GC starvation and near physiological GC exposure.
Metabolite profile changes between a state of GC starvation and near physiological GC exposure.
mRNA/miRNA profile changes between a state of GC starvation and near physiological GC exposure.

All

20 Years to 60 Years (Adult)

NCT02152553

BIOCORT

May 2014

December 2016

June 2, 2014

July 2, 2017

Sahlgrenska University Hospital
Gothenburg, Vastra Gotaland Region, Sweden

NCT01450930

Completed

Pharmacokinetics of Hydrocortisone After Subcutaneous Administration in Chronic Adrenal Insufficiency

Primary Adrenal Insufficiency

Drug: Hydrocortisone intramuscular first
Drug: Hydrocortisone subcutaneously first

Interventional

Phase 2

Bruno Allolio
University of Wuerzburg

Other

Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment

Bioequivalence Study
safety

All

18 Years to 64 Years (Adult)

NCT01450930

PHYSCA-1
2011-002687-25

PHYSCA

November 2011

July 2012

October 13, 2011

August 1, 2012

Dept of Medicine I, Endocrinology and Diabetology, University Hospital Wuerzburg
Wuerzburg, Germany

NCT02277587

Completed

Dual RElease Hydrocortisone Versus conventionAl Glucocorticoid replaceMent Therapy in Hypocortisolism (DREAM)

Primary Adrenal Insufficiency
Secondary Adrenal Insufficiency

Drug: Plenadren
Drug: Conventional glucocorticoid therapy

Interventional

Phase 4

University of Roma La Sapienza

Other

Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment

Change from baseline in measurement of weight at 3 and 6 months
Change from baseline in metabolic status at 3 and 6 months
Evaluation of immunological profile at baseline 3 and 6 months.
(and 5 more...)

All

18 Years to 80 Years (Adult, Older Adult)

NCT02277587

Hyposurrenalism_1

DREAM

March 2014

June 2016

October 29, 2014

June 27, 2017

Department of Experimental Medicine
Rome, Italy

NCT00251836

Completed

Adrenal Function After Living Kidney Donation

Addison Disease
Hypoaldosteronism

Procedure: Laparoscopic hand-assisted donor nephrectomy

Observational

University of Zurich
Ludwig-Maximilians - University of Munich

Other

Observational Model: Cohort
Time Perspective: Prospective

Plasma cortisol response to low-dose ACTH stimulation

All

18 Years to 80 Years (Adult, Older Adult)

NCT00251836

StV 34-2005
RAB-F-02-0046

January 2007

April 2014

November 10, 2005

December 29, 2016

Dept. of Visceral and Transplantation Surgery, University Hospital Zurich
Zurich, Switzerland

NCT00688987

Completed

The Hypothalamic-Pituitary-Adrenal (HPA) Axis as an Effector System in Weight Regulation

Obesity
Addison's Disease

Drug: Hydrocortisone
Dietary Supplement: Isocaloric Diet

Interventional

Not Applicable

Oregon Health and Science University

Other

Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Investigator)
Primary Purpose: Treatment

Amounts of intra-abdominal fat and total fat at the end of the treatment period for each cortisol dose.
Fasting Lipid levels, fat mass by DEXA, post-heparin lipase activity, insulin sensitivity, and fat biopsy

All

18 Years and older (Adult, Older Adult)

NCT00688987

eIRB 545
OCTRI #711

August 2000

July 2004

August 2004

June 3, 2008

June 5, 2008

Oregon Health & Science University
Portland, Oregon, United States

NCT00444119

Completed

Survey in Patients With Chronic Adrenal Insufficiency in Germany

Adrenal Insufficiency
Addison's Disease

Observational

University of Wuerzburg

Other

Observational Model: Defined Population
Time Perspective: Cross-Sectional
Time Perspective: Retrospective/Prospective

All

Child, Adult, Older Adult

NCT00444119

Wü_NNRIS_45/04

May 2004

April 2005

March 7, 2007

Dept of Medicine, Gastroenterology, Hepatology and Endocrinology, Charité Campus Mitte, Charité, University Medicine Berlin
Berlin, Germany
University of Wuerzburg, Dept of Medicine - Endocrine and Diabetes unit
Wuerzburg, Germany

NCT00975078

Completed

Test Predicting Adrenal Insufficiency in Volunteers Under Prednisone Treatment

Adrenal Gland Hypofunction

Procedure: adrenal insufficiency testing
Drug: prednisone

Interventional

Phase 4

University Hospital, Basel, Switzerland

Other

Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic

The primary outcome of this study is the rate of adrenal insufficiency assessed on the 7th day after stopping a 14-days course of corticosteroid therapy with 0.5mg/kg KG prednisone per day.

Male

18 Years and older (Adult, Older Adult)

NCT00975078

DEXA

May 2009

October 2009

September 11, 2009

August 9, 2011

Division of Endocrinology University Hospital Basel
Basel, Switzerland

NCT01452893

Completed

Counterregulatory Hormone Production in Adrenal Insufficiency and Diabetes Type I

Addison's Disease
Adrenal Insufficiency
Diabetes Mellitus Type I

Procedure: Spiroergometry

Observational

University of Wuerzburg

Other

Observational Model: Cohort
Time Perspective: Prospective

difference in cognitive function before and after physical stress
differences in counterregulatory hormonal response to physical stress

All

18 Years to 65 Years (Adult, Older Adult)

NCT01452893

CANDI-1

CANDI

March 2011

May 2012

December 2013

October 17, 2011

January 6, 2014

Dept. of Endocrinology and Diabetology, Dept. of Medicine I, University Hospital Wuerzburg
Wuerzburg, Germany

NCT00001180

Completed

Dose Response Relationship for Single Doses of Corticotropin Releasing Hormone (CRH) in Normal Volunteers and in Patients With Adrenal Insufficiency

Adrenal Gland Hyperfunction
Adrenal Gland Hypofunction
Cushing's Syndrome
Healthy

Drug: Ovine Corticotropin-Releasing Hormone (oCRH)

Observational

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
National Institutes of Health Clinical Center (CC)

NIH

2250

All

Child, Adult, Older Adult

NCT00001180

820045
82-CH-0045

March 1982

June 2005

November 4, 1999

March 4, 2008

National Institute of Child Health and Human Development (NICHD)
Bethesda, Maryland, United States

NCT01371526

Completed

Revival of Stem Cells in Addison's Study

Adrenal Failure

Drug: depot tetracosactide

Interventional

Phase 4

Newcastle University

Other

Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment

Peak serum Cortisol following ACTH stimulation
Change in QoL

All

16 Years to 66 Years (Child, Adult, Older Adult)

NCT01371526

RoSAv1.2:04_10: R&D#5252
2009-018074-56

RoSA

September 2010

September 2012

June 13, 2011

February 6, 2013

Newcastle University
Newcastle upon Tyne, Tyne and Wear, United Kingdom

NCT01793168

Recruiting

Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford

Rare Disorders
Undiagnosed Disorders
Disorders of Unknown Prevalence
(and 260 more...)

Observational

Sanford Health
National Ataxia Foundation
International WAGR Syndrome Association
(and 23 more...)

Other

Observational Model: Case-Only
Time Perspective: Prospective

To accelerate research into rare disorders by connecting individuals who are interested in research and who have been diagnosed with a rare disorder (or a disorder of unknown prevalence, or who are undiagnosed) with researchers who study rare diseases.

20000

All

Child, Adult, Older Adult

NCT01793168

03-10-014
Hypersomnia Foundation
National Ataxia Foundation
4p- Support Group
CdLS Foundation
Hyperacusis Research Limited
Kabuki Syndrome Network
Kawasaki Disease Foundation
Klippel-Feil Syndrome Freedom
Leiomyosarcoma Direct Research
MSS Support Group
ML4 Foundation
Stickler Involved People
IWSA
Soft Bones
PWN4PWN
aHUS
Klippel-Feil Syndrome Alliance
American MEN Support
Kleine-Levin Syndrome
All Things Kabuki
WSS Foundation
BIVA
ABDA
PROS Foundation (HLH)

CoRDS

July 2010

December 2100

February 15, 2013

October 2, 2017

Sanford Health
Sioux Falls, South Dakota, United States

NCT00485186

Withdrawn

Gene Polymorphisms Influencing Steroid Synthesis and Action

Disorders of Sex Development
Congenital Adrenal Hyperplasia
Congenital Adrenal Hypoplasia
(and 3 more...)

Observational

University of Schleswig-Holstein

Other

Observational Model: Family-Based
Time Perspective: Prospective

All

Child, Adult, Older Adult

NCT00485186

D429/05

June 2007

June 2013

June 12, 2007

September 5, 2013

NCT02689960

Completed

Vaginal Prednisone Administration for Prevention of Adrenal Crisis

Adrenal Insufficiency

Drug: 100mg prednisone suppository

Interventional

Phase 2

Wuerzburg University Hospital

Other

Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Prevention

Bioequivalence of vaginal prednisone administration compared to rectal application, assessed by repeated determination of prednisolon levels (in blood)
Safety of the vaginal administration of prednisone compared to rectal application, assessed by the number of participants with treatment-related adverse events (using the NCI-CTC, version 4.0).
Suppressive effects on ACTH levels after vaginal administration of prednisone compared to rectal application, assessed by repeated determination of ACTH-levels
Tolerability by the patients assessed by a questionnaire

Female

18 Years and older (Adult, Older Adult)

NCT02689960

Vapreda

January 2017

April 2017

June 1, 2017

February 24, 2016

June 20, 2017

NCT03426319

Completed

Cardiovascular Status in Adrenal Insufficiency

Adrenal Insufficiency

Diagnostic Test: Cardiovascular evaluation

Observational

Wuerzburg University Hospital

Other

Observational Model: Cohort
Time Perspective: Cross-Sectional

Cardiovascular status - anamnesis
Cardiovascular status - mean systolic blood pressure
Cardiovascular status - mean diastolic blood pressure
(and 10 more...)

All

18 Years and older (Adult, Older Adult)

NCT03426319

CV-CORT-AI

CVCORT-AI

August 2013

June 2014

February 8, 2018

University Hospital Wuerzburg
Wuerzburg, Germany

NCT00915343

Completed
Has Results

Once-daily Oral Modified Release Hydrocortisone in Patients With Adrenal Insufficiency

Adrenal Insufficiency

Drug: hydrocortisone (modified release), oral tablet 20 and 5 mg
Drug: Hydrocortisone, oral tablet, 10 mg

Interventional

Phase 2
Phase 3

Shire

Industry

Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment

Area Under the Concentration Time Curve From Zero to 24 Hours (AUC0-24h) of Total S-cortisol in Plasma After Multiple Doses During Part A
Maximal Concentration (Cmax1) of S-cortisol in Plasma After Single and Multiple Dosing During Part A
Maximal Concentration (Cmax2) of S-cortisol in Plasma After Single and Multiple Dosing During Part A
(and 37 more...)

All

18 Years and older (Adult, Older Adult)

NCT00915343

EudraCT: 2006-0007084-89
104-07

DC 06/02

August 2007

July 2008

January 2009

June 8, 2009

July 20, 2015

† Study has passed its completion date and status has not been verified in more than two years.

To Top

Search Results